在慢性病中确定潜在的抗衰老药物和点
Qian Zhang1, Bing Bai2, Lidan Ran3
1Integrative Medicine & Healthy Center, The First People's Hospital of Zunyi, The Third Affiliated Hospital of Zunyi Medical University, 98 Fenghuang Road, Zunyi, 563002, Guizhou, China. zw19891003@qq.com.
Scientific reports
|May 3, 2025
概括
这项研究确定了与衰老相关的基因和潜在的抗衰老药物,如Cinnamaldehyde,用于治疗慢性病 (CKD). 研究结果表明,针对这些衰老途径可能会延迟CKD的进展,并提供新的治疗策略.
科学领域:
- 生物医学研究的研究.
- 生物信息学是一种生物信息学.
- 基因组学就是基因组学.
背景情况:
- 慢性病 (CKD) 是一种普遍的,无法治疗的疾病,通常与衰老有关.
- 对CKD有效的治疗策略仍然有限.
- 衰老过程显著影响病的发展和进展.
研究的目的:
- 通过生物信息学识别潜在的抗衰老药物和CKD的治疗点.
- 探索将衰老与CKD联系在一起的分子机制.
- 为了发现新的治疗途径来管理CKD.
主要方法:
- 对GEO数据集 (GSE37171,GSE66494) 的分析,以确定差异表达基因 (DEG).
- 整合DEGs与与衰老相关的基因,以精确定位与衰老相关的差异基因 (ARDEGs).
- 使用STRING和Cytoscape构建蛋白质-蛋白质相互作用 (PPI) 网络并识别枢纽基因;通过ceRNA,转录因子网络和DGldb数据库进行药物查.
主要成果:
- 确定了317个DEG和23个ARDEG,其中SOD2,FGF21,FOS,RELA,DDIT4,BMI1,DUSP6,LGALS3,CXCR2和CEPB被突出显示为CKD中的关键调节基因.
- 发现甲作为一种潜在的抗衰老药物,向与衰老相关的与CKD相关的路径.
- 在单边尿道阻塞 (UUO) 动物模型中验证了甲对DDIT4和DUSP6标的减少表达,并证明了甲在减少纤维化标志物的有效性.
结论:
- 这项研究阐明了CKD中与衰老相关的分子标,为开发抗衰老疗法提供了基础.
- 丁甲作为一种有前途的治疗剂,通过调节与衰老相关的途径来延缓CKD的进展.
- 这项研究通过关注其衰老成分,为治疗CKD开辟了新的途径.
相关概念视频
01:33Hormonal Regulation
32.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
01:17Factors Affecting Renal Clearance: Renal Impairment
30
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
30
01:26Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
01:25Antihypertensive Drugs: Direct Renin Inhibitors
439
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
439
01:11Renal Failure: Dose Adjustments
34
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
34